主要文件

查看所有文档

L9664

氯雷他定

Name: 氯雷他定
Brand: SIGMA

≥98% (HPLC), Histamine H1 receptor antagonist, powder

别名:

4-（8-氯-5,6-二氢-11H-苯并[5,6]环庚[1,2-b]吡啶-11-亚基-1-哌啶羧酸乙酯, 氯雷他定

登录查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式（希尔记法）:

C₂₂H₂₃N₂O₂Cl

化学文摘社编号:

79794-75-5

分子量:

382.88

UNSPSC Code:

12352200

PubChem Substance ID:

24278525

NACRES:

NA.77

MDL number:

MFCD00672869

Assay:

≥98% (HPLC)

Form:

powder

Quality level:

200

技术服务

需要帮助？我们经验丰富的科学家团队随时乐意为您服务。

让我们为您提供帮助

属性

产品名称

氯雷他定, ≥98% (HPLC), powder

Quality Level

200

assay

≥98% (HPLC)

form

powder

color

white

solubility

DMSO: soluble 50 mg/mL, H₂O: insoluble

originator

Schering Plough

storage temp.

2-8°C

SMILES string

CCOC(=O)N1CC\C(CC1)=C2/c3ccc(Cl)cc3CCc4cccnc24

InChI

1S/C22H23ClN2O2/c1-2-27-22(26)25-12-9-15(10-13-25)20-19-8-7-18(23)14-17(19)6-5-16-4-3-11-24-21(16)20/h3-4,7-8,11,14H,2,5-6,9-10,12-13H2,1H3

InChI key

JCCNYMKQOSZNPW-UHFFFAOYSA-N

Gene Information

human ... CYP3A4(1576), HRH1(3269), KCNH1(3756), KCNH2(3757), PTAFR(5724)
rat ... Hrh1(24448)

说明

Biochem/physiol Actions

氯雷他定是一种非镇静性组胺H1受体拮抗剂。其可抑制双孔结构域钾通道K2P18.1（也称为TRESK或KCNK18）。

非镇静组胺H₁-受体拮抗剂。

Features and Benefits

该化合物由Schering Plough开发。要浏览其他药物开发化合物和批准的药物/候选药物列表，单击此处。

Still not finding the right product?

Explore all of our products under 氯雷他定

存储类别

11 - Combustible Solids

wgk

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Antiallergic effects of H1-receptor antagonists.

F M Baroody et al.

Allergy, 55 Suppl 64, 17-27 (2001-04-09)

The primary mechanism of antihistamine action in the treatment of allergic diseases is believed to be competitive antagonism of histamine binding to cellular receptors (specifically, the H1-receptors), which are present on nerve endings, smooth muscles, and glandular cells. This notion

Clinical pharmacology of H1-antihistamines in the skin.

F Estelle R Simons et al.

The Journal of allergy and clinical immunology, 110(5), 777-783 (2002-11-06)

The extent of the distribution of H(1)- antihistamines into the skin and H(1)-antihistamine activity in the skin are clinically relevant in the treatment of allergic skin disorders. In a prospective, randomized, double-blind, parallel-group, multiple-dose study, we gave fexofenadine 180 mg

Stimulation of dopa decarboxylase activity in striatum of healthy human brain secondary to NMDA receptor antagonism with a low dose of amantadine.

P Deep et al.

Synapse (New York, N.Y.), 34(4), 313-318 (1999-10-26)

The efficacy of amantadine in alleviating motor symptoms of Parkinson's disease may be mediated in part by stimulation of cerebral dopa decarboxylase (DDC) activity, secondary to antagonism of N-methyl-D-aspartate (NMDA) type glutamate receptors. We tested the specific hypothesis that amantadine

查看所有相关文献

全球贸易项目编号

货号	GTIN
L9664-10MG	04061833966860
L9664-50MG	04061832082769